Aleksandr Vitalevich Amelin

Aleksandr Vitalevich Amelin

Auto-generated profile, based on publicly available information

Aleksandr Vitalevich Amelin

Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NNN.G. Neznanov
N.G. Neznanov
MTMarine Tanashyan
Marine Tanashyan
EAE.S. Akarachkova
E.S. Akarachkova
AAA.V. Amelin
A.V. Amelin
ABA.N. Bogolepova
A.N. Bogolepova
SFS.V. Fedosenko
S.V. Fedosenko
The article presents theses of the resolution of the Interdisciplinary Council of Experts in Psychiatry and Neurology (Moscow, 2024) on the issue of comorbid anxiety disorders (AD) in patients with neurological pathologies. The authors highlight the high prevalence of comorbid ADs and their significant negative impact on the course of underlying diseases, such as epilepsy, pain syndromes and post-stroke conditions. Modern approaches to the diagnosis and treatment of ADs in this group of patients are discussed. Special attention is given to the role of etifoxine as an effective anxiolytic in the comprehensive therapy of ADs. Etifoxine, due to its dual mechanism of action on GABA receptors, demonstrates high efficacy in reducing anxiety and has neuroprotective, neurotrophic, neuroplastic, analgesic, and anti-inflammatory properties, making it an important tool in the treatment of comorbid ADs in patients with neurological pathologies. The article also reviews recently published data confirming its efficacy and favourable safety profile compared to traditional benzodiazepines and other anxiolytic drugs.

14 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VPVladimir Parfenov
Vladimir Parfenov
PKPavel Kamchatnov
Pavel Kamchatnov
DKDina Rustemovna Khasanova
Dina Rustemovna Khasanova
EBEnver Bogdanov
Enver Bogdanov
TLTatiana Markovna Lokshtanova
Tatiana Markovna Lokshtanova
AGAlexey Borisovich Glazunov
Alexey Borisovich Glazunov

19 October 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
ADAlexey B. Danilov
Alexey B. Danilov
MKM. I. Koreshkina
M. I. Koreshkina
EYE. Z. Yakupov
E. Z. Yakupov
AAA. V. Amelin
A. V. Amelin
АAА. A. Artamonov
А. A. Artamonov
One of the key mediator systems involved in the pathogenesis of migraine is the serotonergic system, which led to the development and introduction of serotonin 5-HT1 receptor agonists (triptans) into clinical practice as the most important means of preventing migraine attacks. Serotonin 5-HT1 receptor agonists have a high selectivity for the 5-HT1B and 5-HT1D receptor subtypes, which ensures their effect on the pathogenesis of migraine attack development.Objective: to evaluate the efficacy of a standard dose of Relonova in the relief of four moderate to severe migraine attacks in outpatients in reallife clinical practice, including assessment of the rate of attack relief, the effect of the drug on headache intensity, concomitant symptoms and the general condition of the patient.Material and methods. The study involved 415 patients with migraine (319 women and 96 men; mean age 35.7±7.8 years). A total of 1660 migraine attacks were analyzed. The average number of migraine days per month was 6.72±3.99. Migraine attacks with aura were observed in 125 patients (30.1%). Patients stopped four migraine attacks and filled out self-monitoring diaries. Treatment efficacy was assessed according to the European Headache Federation (EHF) Consensus Algorithm for Determining Effective Treatment of a Migraine Attack.Results. After taking Relonova, pain became mild or disappeared completely in 30 minutes in 52% of patients, in 76% in 1 hour, in 93% in 2 hours, in 99% in 4 hours and in 99% of patients in 24 hours. A recurrence of the headache occurred in 8.8% of the attacks. Additional analgesic treatment after 30 minutes was required in 14% of cases, after which period the frequency did not exceed 2%. Adverse events were observed in 4% of patients and were mild. The overwhelming majority (90%) of study participants were able to successfully terminate three attacks and were responders.Conclusion. Relonova is an effective and safe agent to stop migraine attack and can be recommended for use in daily clinical practice.

24 June 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
GTG. R. Tabeeva
G. R. Tabeeva
AAA. V. Amelin
A. V. Amelin
YVYu. S. Vaganova
Yu. S. Vaganova
NKN. A. Kovalchuk
N. A. Kovalchuk
YTYu. V. Trinitatskiy
Yu. V. Trinitatskiy
ELE. A. Lyakhova
E. A. Lyakhova
Pharmacological treatment of tension-type headache (TTH) attacks involves the selection of the most effective and safe analgesic. However, the choice of medication is limited by the insufficient number of evidence-based studies for this type of headache (HA).Objective: to evaluate the efficacy, safety, and tolerability of fast-release lornoxicam (Xefocam rapid) compared to standard lornoxicam (Xefocam), naproxen, and ibuprofen in relieving headache episodes in patients with frequent episodic TTH in routine clinical practice.Material and methods. The multicenter, observational (non-interventional), prospective RAPID study was conducted in 10 clinical centers across the Russian Federation and included 400 adult patients (74.5% women, 25.5% men) aged 18 to 76 years (mean age: 39.83±12.58 years) with frequent episodic TTH who were prescribed one of the following NSAIDs in routine practice: Xefocam, Xefocam rapid, ibuprofen, or naproxen. The following outcomes were assessed: the number of completely relieved TTH episodes, changes from baseline in the mean number of headache days, mean number of TTH episodes per month, mean duration of TTH episodes, and mean pain intensity on a numerical rating scale, time from drug intake to partial and complete relief of a TTH episode, mean number of days with intake of the drugs in question, number of patients using NSAIDs ≥15 days per month, number of patients taking additional medications for TTH relief, patient satisfaction with the prescribed treatment, number of patients who discontinued treatment, and the frequency of adverse events during therapy.Results. The study demonstrated overall high efficacy of Xefocam and Xefocam rapid in relieving TTH attacks. At the same time, the data obtained allow the identification of some priority effects of investigated drugs. Thus, Xefocam and Xefocam rapid showed the highest efficacy in achieving complete headache relief within 2 hours after intake. Moreover, Xefocam rapid was the most effective across all groups in achieving complete headache relief within the first 30 minutes. The greatest reduction in the numerical rating scale (NRS) score was also observed in the Xefocam rapid and Xefocam groups. In addition, Xefocam and Xefocam use demonstrated the lowest need for additional medications for pain relief among all groups, which may be related to the rapid onset of analgesic action and high safety profile of these drugs. Patients in the Xefocam rapid group more frequently rated their satisfaction with the therapy as excellent.Conclusion. Xefocam rapid showed a high safety profile and excellent tolerability, with the lowest incidence of adverse events among all study groups.

7 June 2025 in The Scientific Notes of the Pavlov University
Verified
Journal Article
Open access
PDF file
AEA. K. Emelianov
A. K. Emelianov
MBM. V. Beletskaya
M. V. Beletskaya
KSK. A. Senkevich
K. A. Senkevich
ALAnna Lavrinova
Anna Lavrinova
ATA. A. Tyurin
A. A. Tyurin
SPSofia Pchelina
Sofia Pchelina
Introduction. The accumulation of neurotoxic forms of alpha-synuclein protein in brain tissues plays a key role in the pathogenesis of Parkinson’s disease (PD). In this case, lysosome dysfunction is considered as one of the possible causes of alpha-synuclein accumulation in cells. The commonality of the pathogenesis of PD and lysosomal storage diseases (LSD) is discussed. Mutations in two genes, GBA1 and SMPD1, leading to the development of Gaucher and Niemann-Pick А/В diseases, respectively, are associated with a high risk of PD development. The contribution of rare variants in other LSD genes is discussed.The objective of this study was to assess the association of rare gene variants of lysosomal storage diseases and Parkinson’s disease in the North-Western region of Russia.Methods and materials. An analysis of data obtained as a result of massive parallel sequencing of 44 genes associated with lysosomal storage diseases was carried out in 496 patients with PD and 401 individuals in the control group.Results.The study revealed a statistically significant difference in the frequency of occurrence of pathogenic and likely pathogenic variants of the LSD genes among patients with PD compared to the control group (p<0.05). An association of pathogenic and opportunistic rare variants of the ARSA and SGSH genes with an increased risk of PD development was revealed.Conclusion. The obtained data confirm the role of rare variants of the LSD genes in PD pathogenesis.